Atrial fibrillation in acute myocardial infarction: A systematic review of the incidence, clinical features and prognostic implications

European Heart Journal

Volumn 30, Issue 9, 2009, Pages 1038-1045

  Schmitt, Joern ^a   Duray, Gabor ^a   Gersh, Bernard J ^b   Hohnloser, Stefan H ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

Acute coronary syndrome; Acute myocardial infarction; Anticoagulation; Atrial fibrillation

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; HEPARIN; LOSARTAN; PLACEBO; SOTALOL; THIENOPYRIDINE DERIVATIVE; TRANDOLAPRIL; WARFARIN;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; CAUSE OF DEATH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STROKE; SYSTEMATIC REVIEW;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CORONARY ANGIOGRAPHY; HOSPITAL MORTALITY; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; PROGNOSIS; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 65949090068     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn579     Document Type: Review

References (56)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-473.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147:1561-1564.
3. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-125.
4. Tsang TS, Miyasaka Y, Barnes ME, Gersh BJ. Epidemiological profile of atrial fibrillation: a contemporary perspective. Prog Cardiovasc Dis 2005;48:1-8.
5. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-952.
6. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 2007;49:986-992.
7. Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 2002;13:399-405.
8. Cha YM, Redfield MM, Shen WK, Gersh BJ. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 2004;109:2839-2843.
9. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-2925.
10. Rathore SS, Berger AK, Weinfurt KP, Schulman KA, Oetgen WJ, Gersh BJ. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation 2000;101:969-974.
11. Roy D, Brugada P, Wellens HJ. Atrial tachycardia facilitating initiation of ventricular tachycardia. Pacing Clin Electrophysiol 1983;6:47-52.
12. GronefeldGC,Mauss O, Li YG, KlingenhebenT,Hohnloser SH. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study. J Cardiovasc Electrophysiol 2000;11:1208-1214.
13. Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet 2001;358:1533- 1538.
14. Bassand JP, Danchin N, Filippatos G, Gitt A, Hamm C, Silber S. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J 2005;26:2733-2741.
15. Ting HH, Rihal CS, Gersh BJ, Haro LH, Bjerke CM, Lennon RJ. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 2007;116:729-736.
16. Armstrong PW. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006;27:1530- 1538.
17. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 2000;140:878-885.
18. Eldar M, Canetti M, Rotstein Z, Boyko V, Gottlieb S, Kaplinsky E. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups. Circulation 1998; 97:965-970.
19. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:406-413.
20. Behar S, Zahavi Z, Goldbourt U, Reicher-Reiss H. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. SPRINT Study Group. Eur Heart J 1992;13:45-50.
21. Goldberg RJ, Yarzebski J, Lessard D, Wu J, Gore JM. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective. Am Heart J 2002;143:519-527.
22. Kinjo K, Sato H, Sato H, Ohnishi Y, Hishida E, Nakatani D. Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol 2003;92:1150-1154.
23. Fang MC, Chen J, Rich MW. Atrial fibrillation in the elderly. Am J Med 2007;120: 481-487.
24. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676.
25. Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 1999;83:477-481.
26. Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van de WF. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-750.
27. GISSI-3-Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3 study protocol on the effects of lisinopril, of nitrates, and of their association in patients with acute myocardial infarction. Am J Cardiol 1992;70:62C-69C.
28. Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001;86:527-532.
29. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006; 152:217-222.
30. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27:512-518.
31. Birnie DH, Gollob M, Healey JS. Clinical trials, the renin angiotensin system and atrial fibrillation. Curr Opin Cardiol 2006;21:368-375.
32. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-1839.
33. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999;20:748-754.
34. Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MS. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J 2005;26:350-356.
35. McMurray J, Kober L, Robertson M, Dargie H, Colucci W, Lopez-Sendon J. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005;45:525-530.
36. Kober L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur J Heart Fail 2006;8:591-598.
37. Madias JE, Patel DC, Singh D. Atrial fibrillation in acute myocardial infarction: a prospective study based on data from a consecutive series of patients admitted to the coronary care unit. Clin Cardiol 1996;19:180-186.
38. Nielsen FE, Sorensen HT, Christensen JH, Ravn L, Rasmussen SE. Reduced occurrence of atrial fibrillation in acute myocardial infarction treated with streptokinase. Eur Heart J 1991;12:1081-1083.
39. Behar S, Tanne D, Zion M, Reicher-Reiss H, Kaplinsky E, Caspi A. Incidence and prognostic significance of chronic atrial fibrillation among 5,839 consecutive patients with acute myocardial infarction. The SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. Am J Cardiol 1992;70:816-818.
40. Siu CW, Jim MH, Ho HH, Miu R, Lee SW, Lau CP. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. Chest 2007;132:44-49.
41. Laurent G, Dentan G, Moreau D, Zeller M, Laurent Y, Vincent-Martin M. Atrial fibrillation during myocardial infarction with and without ST segment elevation. Arch Mal Coeur Vaiss 2005;98:608-614.
42. Kopecky SL. Idiopathic atrial fibrillation: prevalence, course, treatment, and prognosis. J Thromb Thrombolysis 1999;7:27-31.
43. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Impact of congestive heart failure and left ventricular systolic function on the prognostic significance of atrial fibrillation and atrial flutter following acute myocardial infarction. Int J Cardiol 2005;100:65-71.
44. Pedersen OD, Abildstrom SZ, Ottesen MM, Rask-Madsen C, Bagger H, Kober L. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. Eur Heart J 2006; 27:290-295.
45. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870.
46. Stenestrand U, Lindback J,Wallentin L. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation 2005;112: 3225-3231.
47. Rubboli A, Colletta M, Herzfeld J, Sangiorgio P, Di Pasquale G. Periprocedural and medium-term antithrombotic strategies in patients with an indication for longterm anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis 2007;18:193-199.
48. Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008;51:818-825.
49. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA. ACC/ AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-e354.
50. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007;298:1312-1322.
51. Kowey PR, Levine JH, Herre JM, Pacifico A, Lindsay BD, Plumb VJ. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995;92:3255-3263.
52. Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995;92:3264-3272.
53. Chapman MJ, Moran JL, O'Fathartaigh MS, Peisach AR, Cunningham DN. Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. Intensive Care Med 1993;19:48-52.
54. Leak D. Intravenous amiodarone in the treatment of refractory life-threatening cardiac arrhythmias in the critically ill patient. Am Heart J 1986;111:456-462.
55. Sleeswijk ME, Van Noord T, Tulleken JE, Ligtenberg JJ, Girbes AR, Zijlstra JG. Clinical review: treatment of new-onset atrial fibrillation in medical intensive care patients-a clinical framework. Crit Care 2007;11:233.
56. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ. Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. Heart 2002;88:357-362.